BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Roche Registration Ltd submitted on 27 February 1997, to the European Agency for the 
Evaluation of Medicinal Products (EMEA), an application to obtain Marketing Authorisation for the 
medicinal product Mabthera in accordance with the Centralised Procedure falling within the scope of 
Part A of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993. 
The CPMP appointed the Rapporteur and the Co-Rapporteur were: 
Rapporteur:  
H. Hovgaard 
Co-Rapporteur:   Dr. W. F. van der Giesen 
Licensing status : 
The product was not licensed in any country at the time of submission of the application.  
Mabthera has been given a Marketing Authorisation in the following countries: USA on 26 November 
1997, Switzerland on 27 November 1997 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 21 March 1997 
The Rapporteur's first assessment report was circulated to all CPMP Members on 4 June 1997. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  2  June 
1997. 
During the CPMP plenary meeting on 22 July 1997 the CPMP agreed on the consolidated list of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
Company on 22 July 1997. 
The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  12  September 
1997. 
The Rapporteur circulated the response assessment report on the company’s responses to the list 
of  questions  to  all  CPMP  Members  on  28  October  1997.  The  Co-Rapporteur  circulated  the 
responses  assessment  report  on  the  company’s  responses  to  the  list  of  questions  to  all  CPMP 
Members on 7 November 1997. 
The  CPMP  during  its  meeting  on  19  November  1997  decided  to  convene  an  ad-hoc  group  of 
clinical experts in order to give answers to outstanding clinical issues. 
The  ad-hoc  group of clinical  experts  met on 7 January 1998 and the report  from that  meeting 
was circulated to the CPMP members. 
An oral presentation by the company on clinical issues took place during the CPMP meeting on 
27 January 1998.  
The  CPMP,  during  its  meeting  on  27-28  January  1998  discussed  the  recommendations 
presented by the Rapporteur, Co-Rapporteur and the ad-hoc clinical experts group considering 
the  responses  and  additional  follow-up  data  provided  by  the  company.  Amendments  were 
discussed to the Summary of Product Characteristics. 
The CPMP during its meeting of 27-28 January 1998, issued two positive opinions, one for each 
strength, for granting a marketing authorisation to Mabthera on 28 January 1998. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 2 June 1998. 
1/1 
                EMEA 2005 
 
 
 
 
 
